Position in ATYR
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
-$78,877 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
2 quarters on record
Derivatives in ATYR
reported options exposure · as of Jun 30, 2026CallValue
$7,283
CallShares
12,200
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026TORONTO DOMINION BANK holds $769,395,513 across 60 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
2,165,846 | $176,668,057 | |
| 2 | CELC |
Celcuity Inc.
|
1,258,758 | $131,691,261 | |
| 3 | STOK |
Stoke Therapeutics, Inc.
|
3,173,258 | $103,829,001 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
181,432 | $97,419,912 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
85,391 | $42,416,270 | |
| 6 | TARS |
Tarsus Pharmaceuticals, Inc.
|
510,253 | $32,115,323 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
48,783 | $30,418,151 | |
| 8 | NGNE |
Neurogene Inc.
|
681,337 | $21,428,048 |
All Filings in ATYR
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,283 | 12,200 | Call | Defined | 2026-08-14 | |
| 2025-09-30 | $78,877 | 109,400 | Shares | Defined | 2025-11-14 | |
| 2025-09-30 | $78,877 | 109,400 | Put | Defined | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||